BrightGene's BGM0504 Outperforms Novo Nordisk's Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

on

BrightGene Pharmaceutical's investigational drug, BGM0504, showed superior efficacy in reducing blood sugar (HbA1c) compared to Novo Nordisk's semaglutide in a phase 2 trial among Chinese patients with type 2 diabetes12.

After 12 weeks, BGM0504 achieved dose-dependent HbA1c reductions of up to 2.48%, while semaglutide achieved a 1.43% reduction and placebo 0.28%1.

The trial used both double-blind (placebo) and open-label (semaglutide) arms, and also reported similar secondary outcomes, including body weight reduction1.

BGM0504 is a dual GLP-1/GIP receptor agonist being developed for type 2 diabetes and obesity, with studies also showing potential benefits in overweight and non-obese individuals2.

BrightGene is advancing BGM0504 into a head-to-head trial against Eli Lilly’s Zepbound (tirzepatide), with results eagerly anticipated as the next major contest in the competitive GLP-1/GIP field1.

Sources:

1. https://www.fiercebiotech.com/biotech/brightgene-tops-novo-drug-diabetes-ahead-zepbound-showdown

2. https://www.biospace.com/press-releases/brightgene-presents-positive-phase-2-data-for-dual-glp-1r-gipr-agonist-for-weight-management-and-type-2-diabetes-and-preclinical-data-for-novel-amylin-analog-at-american-diabetes-associations-85th-scientific-sessions